{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "Y",
                    "alt": "C",
                    "position": "1699"
                },
                "variant_string_id": "LRRK2 Y1699C"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Mutations in the leucine - rich repeat kinase 2 (LRRK2) gene are the most prevalent known cause of autosomal dominant Parkinson's disease (PD). The LRRK2 gene encodes a Roco protein featuring a ROC GTPase and a kinase domain linked by the C - terminal of ROC (COR) domain. The clinical and neuropathological manifestations of LRRK2 PD are mostly indistinguishable from those observed in sporadic cases of the disease.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations are a cause of autosomal dominant Parkinson's disease and describes the gene's protein structure and its relation to the disease, thus defining the disease mechanism relevant to the functional assay.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "The study used assays such as GTPase assay, co - immunoprecipitation, GST pulldown, competition assay, GTP binding assay, yeast two - hybrid assays to study GTPase activity, dimerization, and interactions within the catalytic core of LRRK2. Dimerization is a common regulatory theme among many protein kinases and has been proposed to be related to GTPase activity in LRRK2 based on the behavior of the C. tepidum Roco protein.",
                    "judgment": "Yes",
                    "reasoning": "The assays effectively model the disease pathogenesis as they are used to study aspects like GTPase activity and dimerization which are hypothesized to be related to the disease mechanism through the role of LRRK2 in PD. These assays are relevant to the defined disease mechanism.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3a: Basic Controls and Replicates",
                    "extracted_paper_info": "Functionality of the GTPase assay was confirmed for each run using the GTPase Gαo from the heterotrimeric G protein family as a control. All protein interactions in yeast two - hybrid assays were assayed in four independent experiments in triplicate. For co - IP and pulldown assays, statistical significance was tested using the Mann - Whitney U test. In quantitative yeast two - hybrid assays, statistically significant differences in the interaction strength of two proteins were determined using a Student's two - tailed t - test.",
                    "judgment": "Yes",
                    "reasoning": "The GTPase assay used a control (Gαo), and multiple replicates were used in yeast two - hybrid assays. Also, statistical tests were used in co - IP, pulldown, and yeast two - hybrid assays, meeting both the requirements of having basic controls and replicates.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3c: Variant Controls",
                    "extracted_paper_info": "The study compared the Y1699C mutant with wild - type LRRK2 and also with other pathogenic mutants like R1441C in terms of GTPase activity and ROC - COR dimerization.",
                    "judgment": "Yes",
                    "reasoning": "The study used known pathogenic variants (R1441C) as controls, meeting the condition for using variant controls in the assay.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "sub_step": "4a: Statistical Analyses",
                    "extracted_paper_info": "For co - IP and pulldown assays, values were tested for significant differences with the Mann - Whitney U test. In quantitative yeast two - hybrid assays, a Student's two - tailed t - test was used to determine statistically significant differences in the interaction strength of two proteins. However, no direct mention of OddsPath calculation.",
                    "judgment": "No",
                    "reasoning": "Although statistical tests were used, there is no mention of calculating OddsPath for the functional data of the Y1699C variant.",
                    "next_step_or_outcome": "Proceed to Sub - step 4b"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "sub_step": "4b: No OddsPath Calculation",
                    "extracted_paper_info": "The study compared the Y1699C mutant with wild - type and other pathogenic mutants (like R1441C) in multiple assays. But the exact number of benign/pathogenic variant controls used across the entire study for this variant's assay is not clearly stated as a count.",
                    "judgment": "Insufficient Information",
                    "reasoning": "Since the paper does not clearly state the total number of benign/pathogenic variant controls used for this variant's assay, we cannot determine if it is 10 or less or at least 11. Considering the information available, we assume a conservative approach and assign the lowest level of evidence strength.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The Y1699C variant in LRRK2 was studied using relevant assays for Parkinson's disease mechanism. Basic controls, replicates, and variant controls were used. However, due to lack of OddsPath calculation and unclear count of variant controls, the functional evidence strength is assigned as PS3_supporting."
        }
    ]
}